Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q2 2018 · 10-Q
Revenue$9.04M$9.04M+156.7% vs Q2 2017 Net Income-$43.85M-$43.85MN/M vs Q2 2017 EPS Diluted-$0.08-$0.08N/M vs Q2 2017 Operating Income-$28,877,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$36,598,000N/M Margins · derivedOperating margin-319.5%+355.9 pt vs Q2 2017
Net margin-485.1%+89.0 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 2, 2018 · 33 d after period end